SoundHound's Vertical AI Penetration Scales Up: Can It Drive Returns?
The company's voice AI engine processed over 2 billion queries in the first quarter. Meanwhile, active restaurant deployments exceeded 13,000 locations, with SoundHound handling approximately 10 million customer interactions each quarter in that segment.
Much of this enterprise momentum is anchored in Amelia 7.0, SoundHound's recently launched agentic AI platform built on its proprietary Agentic Plus framework. Designed to autonomously perform multi-step business workflows, Amelia integrates seamlessly with existing enterprise systems and offers optional human escalation. Early adoption across verticals — including telecom, financial services, healthcare and hospitality — has translated into expanded deployments and contract renewals.
The company also expanded relationships with major clients like a British multinational telecom firm, several global insurers and one of the world's largest hospitality chains. In the first quarter, three healthcare firms renewed and expanded contracts, while four financial institutions grew their deployments of SoundHound's employee-facing AI solutions.
With diversified vertical exposure, fast deployment timelines and a growing base of multimodal AI use cases, SoundHound is starting to reposition itself as a scalable enterprise AI infrastructure provider.
How It Stacks Up to Competitors
C3.ai, Inc. AI is pursuing a partner-led strategy to scale enterprise AI. In the fourth quarter of fiscal 2025, the company reported a 419% year-over-year surge in partner-supported bookings and signed 193 deals through its ecosystem. C3.ai's applications are embedded in Microsoft Azure's sales catalog, enabling Microsoft's global salesforce to co-sell across industries such as manufacturing, chemicals and defense. C3.ai is targeting over 600 enterprise accounts with Microsoft. The company believes partner leverage will be the key to driving long-term scalability and recurring revenues.
BigBear.ai Holdings, Inc. BBAI continues to focus on AI deployments across national security, supply chain and critical infrastructure. BigBear.ai is emphasizing mission-driven engagements, including deployments at the Department of Defense, Los Angeles International Airport and major U.S. shipbuilders. While its backlog reached $385 million, execution is still constrained by government procurement cycles and slower revenue conversion. BigBear's strategy leans heavily on internal R&D, federal contracts and select international pilots, rather than broad commercial scaling.
SOUN's Price Performance, Valuation & Estimates
Shares of SoundHound have gained 54.5% in the past three months compared with the industry 's growth of 23%.
From a valuation standpoint, SOUN trades at a forward price-to-sales ratio of 23.76X, significantly below the industry's average of 19.75X.
The Zacks Consensus Estimate for SoundHound's 2025 and 2026 earnings per share (EPS) implies a year-over-year uptick of 84.6% and 64.1%, respectively. The EPS estimates for 2025 have remained unchanged in the past 30 days.
SoundHound stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Only $1 to See All Zacks' Buys and Sells
We're not kidding.
Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent. Thousands have taken advantage of this opportunity.
Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators, and more, that closed 256 positions with double- and triple-digit gains in 2024 alone.
See Stocks Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
C3.ai, Inc. (AI): Free Stock Analysis Report
BigBear.ai Holdings, Inc. (BBAI): Free Stock Analysis Report
SoundHound AI, Inc. (SOUN): Free Stock Analysis Report
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
29 minutes ago
- Globe and Mail
PBBK Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of PB Bankshares, Inc. Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of PB Bankshares, Inc. (NASDAQ: PBBK) to Norwood Financial Corp is fair to PB Bankshares shareholders. Under the terms of the proposed transaction, PB Bankshares' shareholders will have the option to elect to receive either 0.7850 shares of Norwood common stock or $19.75 in cash for each common share of PB Bankshares they own. The election is subject to proration to ensure that, in the aggregate, 80% of the transaction consideration will be paid in the form of Norwood common stock. Halper Sadeh encourages PB Bankshares shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@ or zhalper@ The investigation concerns whether PB Bankshares and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for PB Bankshares shareholders; (2) determine whether Norwood is underpaying for PB Bankshares; and (3) disclose all material information necessary for PB Bankshares shareholders to adequately assess and value the merger consideration. On behalf of PB Bankshares shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits. We would handle the action on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses. Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors. Attorney Advertising. Prior results do not guarantee a similar outcome.
CTV News
an hour ago
- CTV News
Even without wins, Musk's party may be threat to Trump: analysts
Tesla and SpaceX CEO Elon Musk walks to the stage to speak at the Butler Farm Show, Oct. 5, 2024, in Butler, Pa. (AP Photo/Alex Brandon, file) Donald Trump has shrugged off Elon Musk's plans for a new political party as 'ridiculous' - but the announcement underscored the threat the disaffected former ally poses to U.S. Republicans defending paper-thin congressional majorities. Musk's weekend launch of the 'America Party' came in the wake of Trump signing into law a sprawling domestic policy bill that the tech mogul has slammed over estimates that it will balloon the deficit. Musk has been light on policy detail, but is expected to target a handful of House and Senate seats in next year's midterm elections where the sitting Republican voted for Trump's bill after preaching fiscal responsibility. 'Elon Musk's America Party is a wild card that could upend the midterms in 2026, particularly for Republicans,' said political analyst Matt Shoemaker, a former Republican congressional candidate and an ex-intelligence officer. 'With bare majorities in Congress, the Republicans should be worried.' Musk, the world's richest person, had teased the idea of a new party for weeks, running an informal social media poll in June that showed 80 percent support among 5.6 million respondents. Unlike previous third parties, his would have almost limitless resources, and a talisman with a large constituency of young American men who see him as a maverick genius and a superstar. 'Musk's brand appeals to disaffected independents and younger, tech-savvy voters who might otherwise break for Republicans in swing districts,' Shoemaker told AFP. 'Balance of power' With a personal wealth estimated at $405 billion, Musk has already demonstrated that he is willing to spend big on politics, lavishing $277 million on Trump's 2024 campaign. Yet a more recent foray into Wisconsin politics -- he spent $20 million only to see his candidate for the state supreme court lose handily -- has underlined the limits of wealth and celebrity in politics. And then there is the political difficulty of building support in the American heartland, among voters who are not part of Musk's Silicon Valley 'tech bro' bubble. Time magazine's 2021 Person of the Year was once liked by a broad cross-section of Americans, but he saw his numbers plunge after joining the Trump administration as the president's costcutter-in-chief. Musk's net favorability in the most recent rating published by Nate Silver, one of the most respected U.S. pollsters, is underwater at -18.1, compared with a slightly less subaquatic -6.6 for Trump. 'While you don't want to paint with too broad a brush, the Republican base and MAGA movement are fairly inseparable in today's political climate,' said Flavio Hickel, associate professor of political science at Washington College in Maryland. 'And their support for Trump has been unwavering despite recent controversies. It's hard to imagine any political project associated with Musk siphoning off votes from individuals who approve of Donald Trump.' 'Fizzled out' While multiple Republicans and Democrats have switched to independent, wins for third parties have been rare in modern U.S. history. The Conservative Party of New York State in the 1970s and the Farmer–Labor Party in the 1930s are the only minor parties to win Senate seats in the last century. Smaller parties saw more success in the House in the early 20th century but have only won one seat since the 1950s. AFP spoke to multiple analysts who pointed to the many hurdles thrown in front of third-party candidates trying to get onto the ballot in a system designed to favor the status quo. These include minimum signature requirements, filing fees and other onerous state-specific regulations on age, residency and citizenship. 'Remember in early 2024 the so-called 'No Labels' party that was going to chart a middle course for the 2024 elections?' said veteran political strategist Matt Klink. 'They fizzled out in epic fashion.' Analysts agree that winning seats in Congress may be a stretch, but say Musk can inflict pain on Trump by syphoning votes from vulnerable sitting Republicans or throwing cash at primary opponents of the president's preferred candidates. 'Elon's party won't win seats, but it could cost Republicans plenty,' said Evan Nierman, the founder and CEO of global crisis PR firm Red Banyan. 'In tight districts, even a few points siphoned off from the right could flip control.'
Globe and Mail
2 hours ago
- Globe and Mail
Gastrointestinal Stromal Tumor Pipeline strong with 25+ Companies driving therapeutic innovation: DelveInsight
DelveInsight's, 'Gastrointestinal Stromal Tumors Pipeline Insight 2025' report provides comprehensive insights about 25+ companies and 28+ pipeline drugs in Gastrointestinal Stromal Tumors pipeline landscape. It covers the Gastrointestinal Stromal Tumors pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Gastrointestinal Stromal Tumors pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in the Gastrointestinal Stromal Tumors Pipeline. Dive into DelveInsight's comprehensive report today! @ Gastrointestinal Stromal Tumors Pipeline Outlook Key Takeaways from the Gastrointestinal Stromal Tumors Pipeline Report In June 2025, Merck Sharp & Dohme LLC announced a study to evaluate the efficacy and safety of belzutifan monotherapy in participants with advanced pheochromocytoma/paraganglioma (PPGL), pancreatic neuroendocrine tumor (pNET), von Hippel-Lindau (VHL) disease-associated tumors, advanced wt (wild-type) gastrointestinal stromal tumor (wt GIST), or advanced solid tumors with hypoxia inducible factor-2 alpha (HIF-2α) related genetic alterations. The primary objective of the study is to evaluate the objective response rate (ORR) of belzutifan per response evaluation criteria in solid tumors version 1.1 (RECIST 1.1) by blinded independent central review (BICR). In June 2025, Novartis Pharmaceuticals conducted a study planned a 6-month recruitment phase to enroll 40 subjects, followed by a 6-month treatment phase with monthly visits. Patients benefiting from the treatment could continue during a follow-up phase. In June 2025, Deciphera Pharmaceuticals LLC organized a Phase 1/2 master protocol study is to evaluate if DCC-3009 is safe, tolerable and works effectively in the treatment of GIST. The study will use a modular approach with each module being defined according to therapy: DCC-3009 alone or DCC-3009 in combination with other anticancer therapies. Each module will be conducted in 2 parts: Part 1 (Dose Escalation) and Part 2 (Dose Expansion). Participants will be treated in 28-day treatment cycles with an estimated duration of up to 2 years. DelveInsight's Gastrointestinal Stromal Tumors Pipeline analysis depicts a robust space with 25+ active players working to develop 28+ pipeline treatment therapies. The leading Gastrointestinal Stromal Tumors Companies such as Jiangsu Hengrui Medicine, Daiichi Sankyo Company, Cogent Biosciences, Advenchen Laboratories, Chia Tai Tianqing Pharmaceutical Group, AB Science, Immunicum AB, Novartis, Bristol-Myers Squibb, Hanmi Pharmaceutical Company Limited, GlaxoSmithKline, Ascentage Pharma, Takeda, Array BioPharma, Plexxikon, Arog Pharmaceuticals, Xencor, Inc., DNAtrix, Inc., Onyx Pharmaceuticals, Exelixis, Allarity Therapeutics, Theseus Pharmaceuticals, IDRx, Inc., Allarity Therapeutics, and others. Promising Gastrointestinal Stromal Tumors Therapies such as Belzutifan, Sunitinib, CGT9486, DCC-3116, Ripretinib, UCB4594, and others. Stay ahead with the most recent pipeline outlook for Gastrointestinal Stromal Tumors. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Gastrointestinal Stromal Tumors Approved Drugs Gastrointestinal Stromal Tumors (GIST) Emerging Drugs Famitinib: Jiangsu Hengrui Medicine Famitinib, an orally active, small molecule, is a tyrosine kinase inhibitor against multiple targets, including vascular endothelial growth factor receptor 2/3, platelet-derived growth factor receptor, and stem cell factor receptor (c-kit). Jiangsu Hengrui Medicine Co is developing famitinib against a wide variety of advanced-stage solid cancers. The drug is currently in phase 3 of clinical development for the treatment of Gastrointestinal Stromal Tumors (GIST). Nilotinib: Novartis Tasigna (nilotinib hydrochloride monohydrate) is an orally available signal transduction inhibitor of the Bcr-Abl kinase, c-kit and Platelet Derived Growth Factor (PDGF), all of which play a role in cell proliferation, cell migration, and angiogenesis. Tasigna is specifically indicated for the treatment of chronic phase and accelerated phase Philadelphia chromosome positive chronic myelogenous leukemia (CML) in adult patients resistant or intolerant to prior therapy that included imatinib. The drug is currently being investigated in Phase II clinical trial to evaluate its potential for the treatment of gastrointestinal stromal tumors. THE-630: Theseus Pharmaceuticals THE-630 is a pan-variant inhibitor of the receptor tyrosine kinase KIT. It is designed for patients with advanced GIST whose cancer has developed resistance to earlier lines of therapy by accruing mutations that render those therapies ineffective. In GIST, these mutations occur most often in the KIT protein, where a patient can have multiple KIT mutations simultaneously, leading to complex disease heterogeneity. In preclinical studies, THE-630 demonstrated potent in vitro and in vivo activity against all major classes of KIT activating and resistance mutations in GIST. Moreover, THE-630 achieved predicted pan-variant KIT inhibitory blood concentrations at tolerable doses and was associated with significant anti-tumor activity. Theseus Pharmaceuticals is currently conducting Phase I/II study to evaluate lead candidate, THE-630, in patients with advanced gastrointestinal stromal tumors (GIST). DS 6157: Daiichi Sankyo Company DS-6157 is a potential first-in-class GPR20 targeting ADC and the fifth DXd ADC in the oncology pipeline of Daiichi Sankyo to enter clinical development. ADCs are targeted cancer medicines that deliver cytotoxic chemotherapy ('payload') to cancer cells via a linker attached to a monoclonal antibody that binds to a specific target expressed on cancer cells. Designed utilizing Daiichi Sankyo's proprietary DXd ADC technology, DS-6157 is comprised of a humanized anti-GPR20 monoclonal antibody, which is attached to a novel topoisomerase I inhibitor payload by a tetrapeptide-based linker. The drug is currently in Phase I stage of clinical trial evaluation to treat Gastrointestinal Stromal Tumors. The Gastrointestinal Stromal Tumors pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Gastrointestinal Stromal Tumors with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Gastrointestinal Stromal Tumors Treatment. Gastrointestinal Stromal Tumors Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Gastrointestinal Stromal Tumors Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Gastrointestinal Stromal Tumors market. Explore groundbreaking therapies and clinical trials in the Gastrointestinal Stromal Tumors Pipeline. Access DelveInsight's detailed report now! @ Gastrointestinal Stromal Tumors Treatment Drugs Gastrointestinal Stromal Tumors Companies Jiangsu Hengrui Medicine, Daiichi Sankyo Company, Cogent Biosciences, Advenchen Laboratories, Chia Tai Tianqing Pharmaceutical Group, AB Science, Immunicum AB, Novartis, Bristol-Myers Squibb, Hanmi Pharmaceutical Company Limited, GlaxoSmithKline, Ascentage Pharma, Takeda, Array BioPharma, Plexxikon, Arog Pharmaceuticals, Xencor, Inc., DNAtrix, Inc., Onyx Pharmaceuticals, Exelixis, Allarity Therapeutics, Theseus Pharmaceuticals, IDRx, Inc., Allarity Therapeutics, and others. Gastrointestinal Stromal Tumors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration Oral Parenteral Intravenous Subcutaneous Topical Gastrointestinal Stromal Tumors Products have been categorized under various Molecule types such as Monoclonal Antibody Peptides Polymer Small molecule Gene therapy Unveil the future of Gastrointestinal Stromal Tumors Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Gastrointestinal Stromal Tumors Market Drivers and Barriers Scope of the Gastrointestinal Stromal Tumors Pipeline Report Coverage- Global Gastrointestinal Stromal Tumors Companies- Jiangsu Hengrui Medicine, Daiichi Sankyo Company, Cogent Biosciences, Advenchen Laboratories, Chia Tai Tianqing Pharmaceutical Group, AB Science, Immunicum AB, Novartis, Bristol-Myers Squibb, Hanmi Pharmaceutical Company Limited, GlaxoSmithKline, Ascentage Pharma, Takeda, Array BioPharma, Plexxikon, Arog Pharmaceuticals, Xencor, Inc., DNAtrix, Inc., Onyx Pharmaceuticals, Exelixis, Allarity Therapeutics, Theseus Pharmaceuticals, IDRx, Inc., Allarity Therapeutics, and others. Gastrointestinal Stromal Tumors Therapies- Belzutifan, Sunitinib, CGT9486, DCC-3116, Ripretinib, UCB4594, and others. Gastrointestinal Stromal Tumors Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Gastrointestinal Stromal Tumors Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Get the latest on Gastrointestinal Stromal Tumors Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Gastrointestinal Stromal Tumors Companies, Key Products and Unmet Needs Table of Content Introduction Executive Summary Gastrointestinal Stromal Tumors: Overview Pipeline Therapeutics Therapeutic Assessment Gastrointestinal Stromal Tumors – DelveInsight's Analytical Perspective Late Stage Products (Phase III) Famitinib: Jiangsu Hengrui Medicine Drug profiles in the detailed report….. Mid Stage Products (Phase II) Nilotinib: Novartis Drug profiles in the detailed report….. Early Stage Products (Phase I) DS 6157: Daiichi Sankyo Company Drug profiles in the detailed report….. Inactive Products Gastrointestinal Stromal Tumors Key Companies Gastrointestinal Stromal Tumors Key Products Gastrointestinal Stromal Tumors- Unmet Needs Gastrointestinal Stromal Tumors- Market Drivers and Barriers Gastrointestinal Stromal Tumors- Future Perspectives and Conclusion Gastrointestinal Stromal Tumors Analyst Views Gastrointestinal Stromal Tumors Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
